LONDON - AstraZeneca PLC (LSE:LON:AZN) has announced the appointment of two new Non-Executive Directors to its board. Rene Haas, CEO of Arm, and Birgit Conix, CFO of Sonova, will join the company starting January 1, 2025, and February 1, 2025, respectively.
Chair of AstraZeneca (NASDAQ:AZN), Michel Demaré, expressed confidence in the appointments of Haas and Conix, highlighting their extensive experience and international expertise. Haas is recognized for his deep knowledge of technology, data science, computing, and AI, having led Arm through its most valuable IPO in September 2023. Conix, with a background in finance and over a decade of experience in the pharmaceutical industry, will contribute to the Audit Committee immediately upon her appointment.
Haas, before his current role at Arm, held various leadership positions and was instrumental in diversifying the company's product portfolio and enhancing its software ecosystem. Conix has held senior finance roles at TUI and Telenet Group, and is currently a member of the Supervisory Board of ASML (AS:ASML).
The appointments come as part of AstraZeneca's board refreshment process, with four current Non-Executive Directors nearing the end of their nine-year tenure. The company, a global biopharmaceutical firm based in Cambridge, UK, focuses on prescription medicines across several key areas, including Oncology and Cardiovascular, Renal & Metabolism diseases.
The announcement is based on a press release statement and does not include any endorsements of claims. It provides a factual report of the company's board changes and the professional background of the new appointees.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.